Sharmilan Thanendrarajan
Associate Professor
Also affiliated: University of Bonn (2011–2012); Medical College of Wisconsin (2026); University Hospital Bonn (2012); University of Arkansas Medical Center (2015–2026); Cancer Research And Biostatistics (2015); Netherlands Comprehensive Cancer Organisation (2019)
Internal Med, College of Medicine
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Sharmilan Thanendrarajan, M.D., is an Associate Professor in the Department of Internal Medicine at the University of Arkansas for Medical Sciences, focusing on multiple myeloma research. His work investigates the molecular underpinnings of multiple myeloma, including spatial genomic heterogeneity and the role of specific genes in disease progression and relapse. Dr. Thanendrarajan has published research on the association between hexokinase-2 expression and false-negative PET scans in multiple myeloma, as well as the prognostic significance of total lesion glycolysis by 18F FDG PET/CT and the presence of large focal lesions.
His research also extends to monitoring disease in myeloma patients, exploring the combination of flow cytometry and functional imaging for residual disease detection. Furthermore, Dr. Thanendrarajan has investigated the risk of infections associated with bispecific antibodies in multiple myeloma through pooled analyses. He leads a research group and collaborates extensively with colleagues at the University of Arkansas for Medical Sciences, including Maurizio Zangari, Carolina Schinke, Samer Al Hadidi, and Frits van Rhee. Dr. Thanendrarajan holds board certifications in Internal Medicine and Hematology/Oncology in Germany and is recognized as a highly cited researcher with an h-index of 33 and over 3,800 citations across more than 270 publications.
Research Overview
Sharmilan Thanendrarajan, M.D., is an Assistant Professor of Medicine with the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences.Dr. Thanendrarajan trained as a fellow in Hematology/Oncology at University Clinic of Bonn in Germany. He trained as a resident in Internal Medicine at University Clinic of Bonn and General Hospital of Hagen. Dr. Thanendrarajan earned his M.D. from the Medical College of Ruhr-University in Bochum, Germany. He is a member of the German Society of Internal Medicine, the German Cancer Society, the German Society for Hematology and Oncology, the European Society for Medical Oncology and the European Myeloma Network. Dr. Thanendrarajan is board certified in Germany in Internal Medicine and Hematology/Oncology. Publications: http://www.ncbi.nlm.nih.gov/pubmed/?term=thanendrarajan+sTo make an appointment with Dr. Thanendrarajan, please call 1-888-MYELOMA.
Metrics
- h-index: 33
- Publications: 277
- Citations: 3,884
Positions
-
Associate Professor publications 2015–2026University of Arkansas for Medical Sciences Internal Med, College of Medicine Institutional directory
Selected Publications
-
Correction: Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)
-
New-Onset Sarcoidosis During B-cell Maturation Antigen (BCMA)-Directed T-cell Engager Therapy With Teclistamab in Relapsed/Refractory High-Risk Multiple Myeloma: A Case Report and Mechanistic Insight (2026)
-
Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma (2026)
-
Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study (2025)
-
The efficacy of teclistamab in patients with multiple myeloma and secondary plasma cell leukemia (2025)
-
Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imaging (2025)
-
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025)
-
Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols (2025)
-
Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma (2025)
-
Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma (2025)
-
Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma (2025)
-
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma (2024)
-
The Efficacy of Teclistamab in Multiple Myeloma Patients with Secondary Plasma Cell Leukemia (2024)
-
Application of Stem Cell Boost for Immune Effector Cell Associated Hematotoxicity (ICAHT) Following BCMA Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma (MM) (2024)
-
Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study (2024)
Collaboration Network
Top Collaborators
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
Showing 5 of 163 shared publications
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
Showing 5 of 160 shared publications
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
Showing 5 of 158 shared publications
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma
Showing 5 of 82 shared publications
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma
Showing 5 of 80 shared publications
- Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
- Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
Showing 5 of 64 shared publications
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma
Showing 5 of 57 shared publications
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Long-term outcomes after autologous stem cell transplantation for multiple myeloma
Showing 5 of 53 shared publications
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns
Showing 5 of 44 shared publications
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
Showing 5 of 41 shared publications
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
- The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
Showing 5 of 38 shared publications
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
Showing 5 of 36 shared publications
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
- Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
Showing 5 of 35 shared publications
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma
Showing 5 of 30 shared publications
- Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker
Showing 5 of 27 shared publications
Similar Researchers
Based on overlapping research topics